Similarly, a dose escalation study involving lirafugratinib (RLY-4008), a highly selective oral FGFR2 inhibitor, showed a DCR of 88% and 80% in FGFR inhibitor-naïve CCA and CCA with prior FGFR inhibitor use, respectively.64, 65. Here, FGFR2 is linked to cholangiocarcinoma.